Physician profile
Celia Jauregui
NPI 1487377347
$1,461.51
in general payments reported to CMS, 2019-2025
21 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.91 · 2023: $473 · 2024: $635 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $521.54 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Organon LLC | $148.43 | 2024 | |
| Abbvie INC. | $140.21 | 2023-2025 | |
| Lilly USA, LLC | $106.89 | 2023-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $92.47 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $70.21 | 2022-2024 | Austedo Xr, Ajovy, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $62.21 | 2025 | |
| Alexion Pharmaceuticals, INC. | $41.39 | 2024 | Strensiq |
| Novo Nordisk INC | $37.82 | 2023 | Wegovy |
| Glaxosmithkline, LLC. | $26.45 | 2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $25.19 | 2025 | The Cologuard Plus Collection Kit |
| Corium, LLC | $23.34 | 2023 | Azstarys |
| Xeris Pharmaceuticals, INC. | $23.32 | 2023 | Gvoke Hypopen |
| Amgen INC. | $20.29 | 2023 | Evenity, Prolia |
| Kowa Pharmaceuticals America, INC. | $19.40 | 2025 | Zoryve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.02 | 2023 | Veozah |
| Paratek Pharmaceuticals, INC. | $18.64 | 2025 | Xhance, Nuzyra |
| Merck Sharp & Dohme LLC | $17.45 | 2023 | Pneumovax 23, Vaxneuvance, Rotateq |
| E.R. Squibb & Sons, L.L.C. | $16.54 | 2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $16.07 | 2023 | Trintellix |
| Sanofi Pasteur INC. | $14.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celia Jauregui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.